Merck KGaA to purchase SpringWorks Therapeutics in deal worth more than $3 billion
After months of discussion, Germany’s Merck KGaA said it would buy SpringWorks Therapeutics.
Related Articles
Amid FDA chaos, approval of a rare disease drug gets delayed — again
Stealth BioTherapeutics had expected the FDA to respond on Tuesday to its marketing application for elamipretide to treat Barth syndrome.
With one month to go, few details on RFK Jr.’s MAHA commission
With a May 24 deadline looming, Kennedy’s MAHA commission has held just one full meeting on its goal of reducing childhood chronic disease.
Medicare regulations hamper providers without helping patients
Many Medicare quality measures are only loosely related to actual patient outcomes. It’s time to deregulate the system, writes Emory professor David Howard.
The end of compounded GLP-1 copies leaves many patients in a ‘lose-lose’ position
With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from
Pharma’s reputation with patient groups dips again, mostly due to pricing issues
For the second consecutive year, the pharma industry saw its reputation dip among patient advocacy groups, largely due to ongoing concerns over pricing issues.
U.S. government researchers present ‘phenomenal’ new data on HPV vaccines
A new study seems to confirm that a single dose of the vaccine used to prevent HPV infection is just as effective as two —…
Capricor Therapeutics forges ahead with FDA on Duchenne drug, despite political tumult
While there have been reports from drugmakers about possible interruptions with FDA matters due to staff layoffs, one company “hasn’t noticed any difference.”
U.S. government researchers present ‘phenomenal’ new data on HPV vaccines
A new study seems to confirm that a single dose of the vaccine used to prevent HPV infection is just as effective as two —…
HPV vaccine news ‘that will save millions of lives’ from cancer, and other AACR news
The AACR meeting was full of promising data on the vaccine against cervical cancer, a lung cancer drug and the next generation of KRAS inhibitors.
Let’s talk tariffs, and no Amazon Prime subscription with your MA plan
This is the online version of STAT’s email newsletter Health Care Inc., delivered to your inbox every Monday.